Gresele – Study Gresele et al.

Study design

The Study Gresele at al. is a two-arm clinical trial based at 43 clinical sites throughout Europe. The principal aim of the trial was to investigate the effect of NCX 4016 (800mg/day) versus placebo on walking distance in patients with peripheral arterial occlusive disease. Individuals were eligible for inclusion if they were aged between 40 and 80 years, had Leriche-Fontaine stage II peripheral arterial disease, ankle-brachial index <0.9, absolute claudication distance <500m, initial claudication distance >50m on a standardized treadmill test, and were clinical stable before inclusion. All patients gave their written informed consent.

Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT01256775

Key publications

Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. J Vasc Surg. 2012 Dec;56(6):1622-8, 1628.e1-5